tbuckley/cabot-search huggingface dataset:
FRI0319 The analysis of risk and protective factors for thrombosis in systemic lupus erythematosus with or without antiphospholipid antibodies
Authors: T. Watanabe, K. Oku, O. Amengual, S. Shimamura, I. Nakagawa, A. Noguchi, Y. Kanetsuka, M. Kono, T. Kurita, Y. Fujieda, T. Bohgaki, S. Yasuda, T. Horita, T. Atsumi
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Thrombosis is one of the most frequent manifestations in patients with systemic lupus erythematosus (SLE). In this study, we examined the several risk factors for thrombosis in patients with SLE. Further, we investigated whether some factors could play a protective thrombotic role in SLE. <h3>Objectives</h3> To identify risk and protective factors for thrombosis in SLE. <h3>Methods</h3> Ninety-seven newly diagnosed consecutive patients with SLE without history of thrombotic events were recruited at our hospital from 2001 to 2012. All patients, 87 woman and 10 men, fulfilled the 1997 American College of Rheumatology revised criteria for SLE. Fifty-four patients (55.7%) had antiphospholipid antibodies (aPL). All patients were follow-up since the inclusion until December, 2012. The development of thrombosis were defined as the study endpoint. <h3>Results</h3> The median follow-up period in all patients was 46 months (IQR 17-84 months). In 54 patients with aPL, the median follow-up period was 57 months (IQR 28-99 months). 10 patients with aPL (18.5%) developed thrombosis during the follow-up period. Cerebral infarction (CI) was observed in 5 patients, pulmonary embolism (PE) in 4 and deep vein thrombosis in 3. Multivariate analysis with Cox's proportional hazards model showed that older age at SLE onset and anticardiolipin antibodies (aCL)-IgG positivity, (HR 1.89 for every ten age, 95%C.I. 1.07-3.33) and (HR 5.68, 95%C.I. 1.28-25.3), respectively, are statistically significant risk factor for thrombosis. Statin therapy appears as a statistically significant protective thrombotic factor (HR 0.093, 95%C.I. 0.01-0.82) (Figure 1.). Disease activity, anti-thrombotic agents and risk factors for atherosclerosis were not related to thrombosis. On the other hand, in 43 patients without aPL (median follow-up period 26 months, IQR 12-66 months), 4 patients (9.3%) developed thrombosis. Three patients had CI and one PE. None of the evaluated risk factors correlated to the development of thrombosis in aPL-negative patients. <h3>Image/graph</h3> <h3>Conclusions</h3> This study suggests that, in patients with aPL, the late disease onset and the presence of aCL-IgG represent additional risk factors for thrombosis. Statin treatment appears as a thrombotic protective factor. <b>Disclosure of Interest</b>: None Declared
AB0340 Fecal Calprotectin in Rheumatoid Disease, and Its Relation to Disease State: Table 1.
Authors: M. Tayel, M.H. Abdel Megid, H.H. Nouh, B. Rofaeil
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Calprotectin is a calcium binding protein with antimicrobial activity derived from neutrophils and monocytes. It has a clinical relevance to some inflammatory diseases, mainly inflammatory bowel disease (IBD). Some studies show a correlation with inflammatory rheumatic diseases. <h3>Objectives</h3> to evaluate fecal calprotectin in rheumatoid arthritis (RA) patients (pts) and its correlation to lower GIT symptoms and inflammatory markers. <h3>Methods</h3> Demographic features, clinical presentation, pattern of GIT involvement, mode of therapy, laboratory markers, DAS 28 and fecal calprotectin levels using ELISA were assessed for 50 RA patients (group I) and 20 healthy subjects as control group (group II). <h3>Results</h3> The mean age was 42.4±10.19 yrs in RA pt with no significant difference between group I and II in all demographic data. GIT symptoms are mainly abdominal pains in 75%, constipation in 40%, bloody stools with tenesmus in 15%, and diarrhea in 5%. Two GIT symptoms were reported by more than 35% of pts. Mean fecal calprotectin level was 56±10.27 ug/g and 38.12±6.11 ug/g for group I and II, with high stastistical difference (p=0.008). There is a significant increased level of fecal calprotectin in positive cases of RF, with increased CRP and ESR and high DAS 28. Also, there was is statistically significant relation between GIT symptoms and NSAIDs intake, and between fecal calprotectin levels and the use of NSAIDs, steroids and salycilates. <h3>Conclusions</h3> GIT symptoms are not uncommon in RA. Calprotectin fecal assay correlates positively with GIT symptoms severity and frequency, laboratory markers of disease activity and DAS 28 could be a simple non invasive tool to identify patients with NSAID entropathy. <h3>References</h3> Garcia-Arias M, Pascual-Salcedo D, Ramiro S, et al. Calprotectin in rheumatoid arthritis. Molecular diagnosis and therapy 2013; 17: 49-56. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3345
SAT0490 Vitamin D Serum Levels Correlate with Bone Mass Values in Postmenopausal Systemic Sclerosis Patients
Authors: S. Paolino, B. Seriolo, A. Casabella, A. Sulli, C. Pizzorni, G. Botticella, M. Meroni, M. Cutolo
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Vitamin D is involved in both innate and adaptive immunity and in the regulation of bone turnover<sup>1</sup>. High prevalence of vitamin D deficiency has been reported in autoimmune disease including Systemic Sclerosis (SSc)<sup>2</sup>. Vitamin D is recognized as one of the important causal factor for low bone mass due to its action on bone formation and mineralization<sup>3,4</sup>. Moreover SSc is characterized by vascular damage, immune and fibrotic changes that are further risk factors for bone mass loss. <h3>Objectives</h3> The aim of this study was to evaluate possible correlation between 25(OH)D<sub>3</sub> serum concentration and further bone mass loss in postmenopausal women with SSc in winter season. <h3>Methods</h3> After informed consent 54 female SSc patients and 42 healthy controls (mean age 68.5±9.5 years), were enrolled in the study during routine screening programs, in winter time. The mean age of patients was 66.5±11 years, the mean disease duration calculated from onset of Raynaud phenomenon was 12±10 years. 25(OH)D<sub>3</sub> serum levels were evaluated by radioimmunoassay. The Bone Mineral Density (BMD) of the lumbar spine and hip was measured by dual energy X-ray absorptiometry using a Lunar Prodigy (GE, USA) <h3>Results</h3> 25(OH)D<sub>3</sub> resulted significantly lower in SSc patients in comparison with controls (mean ± SD 16.1±11.7 vs 25.1±4.1 ng/ml p&lt;0.01); whereas several bone metabolism markers like calcium (p=0.2), phosphorus (p=0.1) and bone alkaline phosphatase (p=0.1) serum levels were similar in both groups. BMD was significantly lower in SSc patients compared to control group at the level of femoral neck (mean ± SD 0.766±0.13 g/cm<sup>3</sup> vs 0.896±0.3 g/cm<sup>3</sup>, p&lt;0.001) and total femur (0.826±0.163 g/cm<sup>3</sup> vs 0.948±0.136 g/cm<sup>3</sup> p&lt;0.002). Significantly lower BMD at lumbar spine was also observed in SSc patients (1.033±0.151 g/cm<sup>3</sup> vs 1.132±0.200 g/cm<sup>3</sup> p&lt;0.003). Both BMD of femoral neck and total femur positively correlated with 25(OH)D<sub>3</sub> concentrations (r=0.39, p&lt;0.002; r=0.46, p&lt;0.003, respectively). <h3>Conclusions</h3> 25(OH)D<sub>3</sub> serum concentration and BMD values are significantly lower in SSc postmenopausal patients than in postmenopausal controls, at least in winter time. A positive correlation between 25(OH)D<sub>3</sub> serum levels and bone mass seem evident in SSc patients and deserve further analysis. <h3>References</h3> Cutolo M. et al. Autoimmun Rev 2011;11:84-87. Caramaschi P. et al. Clin Rheumatol 2010;12:1419-25. Lips P. et al. Journal of Internal Medicine 2006; 260:245–254. Pelajo CF et al Autoimmun Rev 2010 9(7):507-510. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4087
GE-27 * THERAPEUTIC IMPLICATIONS OF MEDULLOBLASTOMA SUBGROUPS IN CHILDREN OVER AGE 3: A SINGLE CENTRE POPULATION BASED EXPERIENCE
Authors: V. Ramaswamy, M. Remke, J. Adamski, U. Bartels, U. Tabori, A. Huang, M. Taylor, E. Bouffet
Journal: Neuro-Oncology (2014)

OBJECTIVES: The advent of integrated genomics has fundamentally changed our understanding of medulloblastoma. Although survival differences have been shown to exist between the four principle subgroups, treatment related differences have yet to be elucidated. We sought to delineate these differences at a large referral centre. METHODS: All patients over age 3 treated with surgery, craniospinal irradiation and adjuvant chemotherapy were identified at the Hospital for Sick Children in Toronto from 1998-2012. RESULTS: Ninety-four patients were identified who met our inclusion criteria. Two periods were identified, those patients treated prior to 2006 as per the open protocols of the Children's Oncology Group (CCG9961, POG9631), and patients treated after 2006 treated as per the SJMB03 protocol. Five-year progression free survival over the entire cohort was 78%. When stratified by treatment, 5 year survival pre and post 2006 were identical (76.8% pre-2006 and 79.3% post-2006). When re-analysed in a subgroup specific manner, we find no significant differences in progression-free survival pre and post 2006. Strikingly, we found that Group 3 and 4 patients have excellent survivals compared to those previously reported, with 5 year progression-free survival in average risk Group 4 patients of over 90% and over 75% in average risk Group 3 patients regardless of treatment protocol. SHH patients did relatively poorly across both treatment protocols with 5 year progression free survival of 60% likely owing to a high proportion of TP53 mutated patients. CONCLUSIONS: In a cohort of homogenously treated patients over age 3, progression free survival appears to be improved compared to initial reports based on retrospective cohorts. The impact of subgroup affiliation in children over age 3 needs to assessed in large prospectively treated cooperative protocols to determine the subgroup specificity of treatment regiments.
INFORMATION CONTENT OF INITIAL MYOCARDIAL PERFUSION IMAGE: COMPARISON WITH UPTAKE OF Tc99m HEXAMIBI.
Authors: Georges Y. Baillet, Ismael G. Mena, John M. Robertson, William J. French
Journal: Clinical Nuclear Medicine (1987)

Baillet, Georges Y.; Mena, Ismael G.; Robertson, John M.; French, William J. Author Information
Treatment of Ovarian Carcinoma: Possibilities for Progress
Authors: Charles M. Bagley, Robert C. Young, George P. Canellos, Vincent T. DeVita
Journal: New England Journal of Medicine (1972)

OVARIAN carcinoma is the fourth most frequent cause of death from cancer among women.1 Approximately 14,000 new cases are diagnosed each year, of which 10,000 will eventually be fatal.1 In about 1/2 of all patients, the tumor is amenable to primary resection. However, even after what appears to be complete removal of the disease, a recurrence requiring further treatment will develop in about 20 to 50 per cent of these cases.2 , 3 Radiation therapy has been extensively used as an adjunct to primary surgery. Gratifying results have been achieved in many patients, especially with localized disease, but the limited success with . . .
Plasmacytoid Dendritic Cells (PDC) and B Cells Are the Origin of IL-10 in Human PBMC Stimulated by Immunostimulatory Sequence Oligodeoxynucleotides (ISS-ODN)
Authors: J. Lee, H. Park, J. Bahn, Y. Kim, S. Cho, K. Min, Y. Kim, K. Jung
Journal: Journal of Allergy and Clinical Immunology (2006)
Abstract P4-11-02: NovelBRCA1andBRCA2genomic rearrangements in Southern Chinese breast/ovarian cancer patients
Authors: A Kwong, EKO Ng, FBF Law, A Wa, CLP Wong, CHN Wong, AW Kurian, DW West, JM Ford, ESK Ma
Journal: Cancer Research (2012)

Abstract Background and Aims: Germline mutations in the two breast cancer susceptibility genes, BRCA1 and BRCA2 account for a significant portion of hereditary breast/ovarian cancer. Most of the BRCA mutations reported in Southern Chinese patients were point mutations, small deletions, and insertions. The spectrum of large genomic rearrangement (LGR) is largely unknown. Here we perform the first study on the LGR of BRCA genes in a Hong Kong Chinese population. We aimed to determine the spectrum of BRCA LGRs in Southern Chinese patients with breast cancer. Methods: A total of 555 clinically high-risk breast and/or ovarian cancer patients were recruited from the Hong Kong Hereditary Breast Cancer Family Registry, diagnosed from March 2007 to November 2011. Multiplex ligation-dependent probe amplification (MLPA) for detecting BRCA LGRs together with comprehensive BRCA1 and BRCA2 gene sequencing of all coding exons were performed. cDNA sequencing of the LGRs was performed to locate the breakpoint of the deletions. Results: Overall BRCA1/2 mutation prevalence among this cohort was 12.4% (69/555). Among the 69 mutations identified, 4 novel LGRs (2 in BRCA1 and 2 in BRCA2) were detected only by MLPA but not full gene sequencing. Overall the LGR genes accounted for 5.8% (4/69) of all BRCA mutations in our cohort, 6.9% (2/29) of all BRCA1 mutations and 5% (2/40) of all BRCA2 mutations. Conclusions: These findings highlight the LGR spectrum of BRCA1 and BRCA2 genes in Southern Chinese breast cancer patients. LGR testing together with BRCA1/2 full gene sequencing is superior to other methods for comprehensive BRCA1/2 analysis in clinical settings. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-11-02.
Hematopoietic Age at Onset of Triple-Negative Breast Cancer Dictates Disease Aggressiveness and Progression
Authors: Timothy Marsh, Irene Wong, Jaclyn Sceneay, Amey Barakat, Yuanbo Qin, Andreas Sjödin, Elise Alspach, Björn Nilsson, Sheila A. Stewart, Sandra S. McAllister
Journal: Cancer Research (2016)

Abstract Triple-negative breast cancer (TNBC) is considered an early onset subtype of breast cancer that carries with it a poorer prognosis in young rather than older women for reasons that remain poorly understood. Hematopoiesis in the bone marrow becomes altered with age and may therefore affect the composition of tumor-infiltrating hematopoietic cells and subsequent tumor progression. In this study, we investigated how age- and tumor-dependent changes to bone marrow–derived hematopoietic cells impact TNBC progression. Using multiple mouse models of TNBC tumorigenesis and metastasis, we found that a specific population of bone marrow cells (BMC) upregulated CSF-1R and secreted the growth factor granulin to support stromal activation and robust tumor growth in young mice. However, the same cell population in old mice expressed low levels of CSF1R and granulin and failed to promote tumor outgrowth, suggesting that age influences the tumorigenic capacity of BMCs in response to tumor-associated signals. Importantly, BMCs from young mice were sufficient to activate a tumor-supportive microenvironment and induce tumor progression in old mice. These results indicate that hematopoietic age is an important determinant of TNBC aggressiveness and provide rationale for investigating age-stratified therapies designed to prevent the protumorigenic effects of activated BMCs. Cancer Res; 76(10); 2932–43. ©2016 AACR.
Surgeon is struck off for catalogue of failings in care of six patients who died
Authors: Clare Dyer
Journal: BMJ (2016)

A consultant general and gastrointestinal surgeon has been struck off after a regulatory tribunal found that his skills and knowledge fell “far below the standard expected from a consultant surgeon” and that he was guilty of a catalogue of failings amounting to serious misconduct in treating six patients who died in his care.

Dugal Heath, 59, was considered a leading bariatric surgeon before a string of patient deaths prompted his employer, the Whittington Health NHS Trust in London, to commission an independent review by experts from the Royal College of Surgeons. The reviewers found serious deficiencies, and Heath was referred to the General Medical Council (GMC) in 2013.

Only the previous year Heath had …
Fulminant Liver Failure in Association with the Emetic Toxin of<i>Bacillus cereus</i>
Authors: Hellmut Mahler, Aurelio Pasi, John M. Kramer, Petra Schulte, Anne C. Scoging, Walter Bär, Stephan Krähenbühl
Journal: New England Journal of Medicine (1997)

A 17-year-old boy and his father had acute gastroenteritis after eating spaghetti and pesto that had been prepared four days earlier. Within two days, fulminant liver failure and rhabdomyolysis developed in the boy and he died. The father had hyperbilirubinemia and rhabdomyolysis but recovered. We investigated the cause of these illnesses.
OP25 * TIME FROM REFERRAL TO FIRST DEFINITIVE TREATMENT OF PATIENTS DIAGNOSED WITH HIGH-GRADE (WHO GRADE III OR IV) INTRA-CRANIAL GLIAL TUMOURS AT A REGIONAL NEUROSURGICAL CENTRE
Authors: S. S. Talibi, H. U. Qureshi, C. James, S. Giridharan, H. Brydon
Journal: Neuro-Oncology (2014)

INTRODUCTION: In 2006, NICE published guidelines for referral pathways in patients diagnosed with high-grade (WHO grade III-or-IV) intra-cranial glial tumours. Referrals should be made to the regional neuro-oncology MDT in-order to form consensus on optimal management plan and minimise any subsequent delay. Objective is to identify delays and time from referral to 1st-definitive treatment. METHOD: Retrospective review over 6-months. 34 patients with de novo high-grade (WHO grades III-or-IV) intra-cranial gliomas on histology, and age >18-years. Data was collected from the neurosurgery operative records, neurosciences MDT records, and patients' medical notes. RESULTS: 34 patients (13M:21F) underwent biopsy, debulking or debulking with use of gliadal wafers. Mean age was 67.8 years (range 44.1-84.6). Median in-patient stay was 7-days (range 2-46). 4 patients underwent emergency surgery before MDT. Median time interval from the GP-referral to operative intervention was 18.5-days (range 10-38). Median time interval from 1st-diagnostic scan to operative intervention was 16-days (interquartile range: 8.5-26.5). Median time interval from 1st-diagnostic scan to post-operative MDT was 25-days (IQ: 19-35.6). Median time interval from 1st-diagnostic scan to oncology appointment was 40-days (IQ: 32.2-49.5). CONCLUSION: The centre is compliant with NICE-guidelines recommendation of 1-month from 1st-diagnosis to 1st-definitive treatment and 2-months for GP-referrals. Our data is also comparable to another similar published series.
OP0183 Jadas Remission and Minimal Disease Activity upon First Biologic in Jia:
Authors: G. Horneff, S. Von Stackelberg, I. Foeldvari, J.P. Haas, G. Ganser, K. Minden, A. Hospach
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Remission and minimal disease activity have been proposed as treatment goal as both can be achieved. For both JADAS based definitions have been proposed. <h3>Methods</h3> This retrospective analysis used data of the German BIKER-registry the course of JADAS10 (Physician global assessment VAS 0–10-cm, Parent/patient global assessment VAS 0–10-cm, Active joint count 0-71, truncated at 10, normalized ESR [ESR-20/10], range 0-40) upon first biologic regimen. A JADAS&lt;1 was used to define remission, JADAS&lt;3.8/&lt;2 were used as cut-off to define minimal disease activity in polyarticular course/oligoarthritis pts. <h3>Results</h3> 2111 JIA pts starting a first biologic were identified. 1830 received Etanercept (ETA), 209 Adalimumab (ADA) and 33 Tocilizumab (TCZ). Biologics not approved for first line therapy (Abatacept, Anakinra, Infliximab, Golimumab) were used in of 39 pts only. Therefore analysis of the latter patient cohorts seemed not reasonable. Baseline parameters differed for the chosen drugs group. Patients receiving ADA first more often have had chronic uveitis and were more often ANA positive. Age at onset, disease duration, distribution of JIA categories and pretreatments were comparable between ETA and ADA, while TCZ was used more frequently in systemic JIA (table 1). Disease activity indicators at baseline were highest in the ETA group followed by TCZ and lowest with ADA. ESR&amp; CRP were highest in TCZ starters. Upon treatment, the median JADAS decreased in all JIA categories. After 12 months on treatment with ETA, depending of the JIA categories, 28% to 42% of pts had a JADAS&lt;1 defining remission, minimal disease activity (JADAS&lt;3.8) was reached by 50-69% of polyarticular JIA pts and 69% in oligoarticular JIA (JADAS&lt;2). The rates further increased over the treatment time. Similar rates for remission and low disease activity were reached with ADA. Because mostly systemic JIA patients were recruited in the TCZ cohort, results were not directly comparable. <h3>Conclusions</h3> ETA is by far the most frequently used biologic in JIA pts. ADA is preferred in pts with a history of uveitis, while TCZ is preferred in systemic JIA. Minimal disease activity is reached by the majority of pts but remission only by a part. In summary, a treat to target approach seems reasonable in JIA patients. New therapeutic options are needed for JIA patients with refractory disease. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2336
Abstract ADV02: Black voices on health: Exploring possibilities for community-based research on cancer and co-morbidities amongst rural California Central Coast African Americans.
Authors: Carmelita Austin-Schreher
Journal: Cancer Research (2013)

Abstract Carmelita Austin-Schreher, a breast cancer survivor who wanted to connect African-Americans to early detection education, support and services formed the African-American Community Health Group of the Central Coast with-in 4 months of her diagnosis. Beginning in 1998, we responded as a self-help group to the disproportionately high breast cancer mortality rates of African-American women, and the need for ethnically sensitive services. Carmelita and community members envisioned a group that would not only educate the African-American community about cancer, but one that would provide one-to-one and group support, a safe and comfortable environment for discussion, and would respect the cultural needs of our community. In order to provide its participants with the highest level of care and education, African-American Community Health Group is committed to staying on top of the latest news in health and cancer screening, treatment and research. African-American Community Health Group is proud of being a “grassroots” organization and is therefore dedicated to providing comprehensive screening outreach, health education, and long-term advocacy to empower all African-Americans in the central coast community. We continue to provide crucial cancer education and prevention services as well as peer support for people with cancer through targeted projects. However, in addition to these activities we expanded health promotion and disease prevention activities of our organization to providing broad-based health education to the larger African-American and underserved communities including men and families, through office hours, library, support groups, seminars, peer and leadership training, and health fairs. The mission of the African-American Community Health Group is to empower the African-American community of the central coast to be active and informed health consumers and survivors through self-help activities, advocacy training, and health education. Additionally, we work to create a dialogue with the community at large about racial disparities in health and the need for increased cultural and racial sensitivity. Citation Format: Carmelita Austin-Schreher. Black voices on health: Exploring possibilities for community-based research on cancer and co-morbidities amongst rural California Central Coast African Americans. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr ADV02. doi:10.1158/1538-7445.AM2013-ADV02